Heart valve repair patients: which blood thinner is safest?
NCT ID NCT07007143
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the best blood-thinning medicine after a minimally invasive heart valve repair for mitral regurgitation, a common heart condition. About 1,032 participants will be randomly assigned to take either aspirin alone or aspirin plus clopidogrel. The goal is to see which approach causes fewer bleeding problems over one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin and clopidogrel (blood thinners)
What this could lead to
If successful, this could establish a safer standard blood-thinning regimen after mitral valve repair, reducing bleeding complications while maintaining effectiveness.
What could go wrong
This is a Phase 4 trial, so the drugs are already approved, but the optimal combination for this specific procedure is unknown. Results may not apply to all patients, and bleeding risks remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences, Fuwai Hospital
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••